> top > docs > PubMed:28784657 > annotations

PubMed:28784657 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-58 Sentence denotes Cholecalciferol, Calcitriol, and Vascular Function in CKD:
T2 59-92 Sentence denotes A Randomized, Double-Blind Trial.
T3 93-119 Sentence denotes BACKGROUND AND OBJECTIVES:
T4 120-256 Sentence denotes High circulating vitamin D levels are associated with lower cardiovascular mortality in CKD, possibly by modifying endothelial function.
T5 257-387 Sentence denotes We examined the effect of calcitriol versus cholecalciferol supplementation on vascular endothelial function in patients with CKD.
T6 388-434 Sentence denotes DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:
T7 435-628 Sentence denotes We performed a prospective, double-blind, randomized trial of 128 adult patients with eGFR=15-44 ml/min per 1.73 m(2)and serum 25-hydroxyvitamin D level <30 ng/ml at the University of Colorado.
T8 629-747 Sentence denotes Participants were randomly assigned to oral cholecalciferol (2000 IU daily) or calcitriol (0.5 μg) daily for 6 months.
T9 748-823 Sentence denotes The primary end point was change in brachial artery flow-mediated dilation.
T10 824-960 Sentence denotes Secondary end points included changes in circulating markers of mineral metabolism and circulating and cellular markers of inflammation.
T11 961-969 Sentence denotes RESULTS:
T12 970-1023 Sentence denotes One hundred and fifteen patients completed the study.
T13 1024-1137 Sentence denotes The mean (SD) age and eGFR of participants were 58±12 years old and 33.0±10.2 ml/min per 1.73 m(2), respectively.
T14 1138-1203 Sentence denotes There were no significant differences between groups at baseline.
T15 1204-1623 Sentence denotes After 6 months, neither calcitriol nor cholecalciferol treatment resulted in a significant improvement in flow-mediated dilation (mean±SD percentage flow-mediated dilation; calcitriol: baseline 4.8±3.1%, end of study 5.1±3.6%; cholecalciferol: baseline 5.2±5.2%, end of study 4.7±3.6%); 25-hydroxyvitamin D levels increased significantly in the cholecalciferol group compared with the calcitriol group (cholecalciferol:
T16 1624-1677 Sentence denotes 11.0±9.5 ng/ml; calcitriol: -0.8±4.8 ng/ml; P<0.001).
T17 1678-1912 Sentence denotes Parathyroid hormone levels decreased significantly in the calcitriol group compared with the cholecalciferol group (median [interquartile range]; calcitriol: -22.1 [-48.7-3.5] pg/ml; cholecalciferol: -0.3 [-22.6-16.9] pg/ml; P=0.004).
T18 1913-1925 Sentence denotes CONCLUSIONS:
T19 1926-2074 Sentence denotes Six months of therapy with calcitriol or cholecalciferol did not improve vascular endothelial function or improve inflammation in patients with CKD.
T1 0-58 Sentence denotes Cholecalciferol, Calcitriol, and Vascular Function in CKD:
T2 59-92 Sentence denotes A Randomized, Double-Blind Trial.
T3 93-119 Sentence denotes BACKGROUND AND OBJECTIVES:
T4 120-256 Sentence denotes High circulating vitamin D levels are associated with lower cardiovascular mortality in CKD, possibly by modifying endothelial function.
T5 257-387 Sentence denotes We examined the effect of calcitriol versus cholecalciferol supplementation on vascular endothelial function in patients with CKD.
T6 388-434 Sentence denotes DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:
T7 435-628 Sentence denotes We performed a prospective, double-blind, randomized trial of 128 adult patients with eGFR=15-44 ml/min per 1.73 m(2)and serum 25-hydroxyvitamin D level <30 ng/ml at the University of Colorado.
T8 629-747 Sentence denotes Participants were randomly assigned to oral cholecalciferol (2000 IU daily) or calcitriol (0.5 μg) daily for 6 months.
T9 748-823 Sentence denotes The primary end point was change in brachial artery flow-mediated dilation.
T10 824-960 Sentence denotes Secondary end points included changes in circulating markers of mineral metabolism and circulating and cellular markers of inflammation.
T11 961-969 Sentence denotes RESULTS:
T12 970-1023 Sentence denotes One hundred and fifteen patients completed the study.
T13 1024-1137 Sentence denotes The mean (SD) age and eGFR of participants were 58±12 years old and 33.0±10.2 ml/min per 1.73 m(2), respectively.
T14 1138-1203 Sentence denotes There were no significant differences between groups at baseline.
T15 1204-1623 Sentence denotes After 6 months, neither calcitriol nor cholecalciferol treatment resulted in a significant improvement in flow-mediated dilation (mean±SD percentage flow-mediated dilation; calcitriol: baseline 4.8±3.1%, end of study 5.1±3.6%; cholecalciferol: baseline 5.2±5.2%, end of study 4.7±3.6%); 25-hydroxyvitamin D levels increased significantly in the cholecalciferol group compared with the calcitriol group (cholecalciferol:
T16 1624-1677 Sentence denotes 11.0±9.5 ng/ml; calcitriol: -0.8±4.8 ng/ml; P<0.001).
T17 1678-1912 Sentence denotes Parathyroid hormone levels decreased significantly in the calcitriol group compared with the cholecalciferol group (median [interquartile range]; calcitriol: -22.1 [-48.7-3.5] pg/ml; cholecalciferol: -0.3 [-22.6-16.9] pg/ml; P=0.004).
T18 1913-1925 Sentence denotes CONCLUSIONS:
T19 1926-2074 Sentence denotes Six months of therapy with calcitriol or cholecalciferol did not improve vascular endothelial function or improve inflammation in patients with CKD.